Shepard, CW, Finelli, L, Alter, MJ. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases
2005; 5: 558–567.
Galea, S, Vlahov, D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Reports
2002; 117: S135– 145.
van de Laar, TJ, et al.
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS
2010; 24: 1799–1812.
Gamage, DG, et al.
Incidence of hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study. BMC Infectious Diseases
2011; 11: 39.
Zickmund, S, et al.
‘They treated me like a leper’. Stigmatization and the quality of life of patients with hepatitis C. Journal of General Internal Medicine
2003; 18: 835–844.
Edlin, BR. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. International Journal of Drug Policy
2004; 15: 81–91.
Miller, N, et al.
Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Academic Medicine: Journal of the Association of American Medical Colleges
2001; 76: 410–418.
Stoove, M, Gifford, S, Dore, G. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence
2005; 77: 81–86.
Applied Economics. Economic evaluation of hepatitis C in Australia. Sydney: Australian Government Department of Health and Ageing, 2005.
Maheshwari, A, Ray, S, Thuluvath, PJ. Acute hepatitis C. Lancet
2008; 372: 321–332.
Seeff, L. Natural history of chronic hepatitis C. Hepatology
2002; 36: S35–46.
Buehler, J. Surveillance. In: Rothman, KJ, Greenland, S, eds. Modern Epidemiology, 2nd edn.
Philedelphia, PA: Lippincott-Raven, 1998.
Centers for Disease Control and Prevention. Guidelines for viral hepatitis surveillance and case management. Atlanta, GA, 2005.
Kamal, SM. Acute hepatitis C: prospects and challenges. World Journal of Gastroenterology
2007; 13: 6455–6457.
Kamal, SM, et al.
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology
2006; 130: 632–638.
Jaeckel, E, et al.
Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine
2001; 345: 1452–1457.
Dore, GJ, et al.
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology
2010; 138: 123–135.e122.
Martin, NK, et al.
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology
2012; 55: 49–57.
Martin, NK, et al.
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One
2011; 6: e22309.
Martin, NK, Vickerman, P, Hickman, M. Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology
2011; 274: 58–66.
Martin, NK, et al.
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology
2011; 54: 1137–1144.
Vickerman, P, Martin, N, Hickman, M. Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug and Alcohol Dependence
2011; 113: 83–85; discussion 86–87.
World Health Organization. Protocol for the assessment of national communicable disease surveillance and response systems. World Health Organisation Department of Communicable Disease Surveillance and Response, 2001.
Centers for Disease Control and Prevention. Updated guidelines for evaluating public health surveillance systems: recommendations from the guidelines working group. Morbidity and Mortality Weekly Report
Overhage, JM, Grannis, S, McDonald, CJ. A comparison of the completeness and timeliness of automated electronic laboratory reporting and spontaneous reporting of notifiable conditions. American Journal of Public Health
2008; 98: 344–350.
European Centre for Disease Prevention and Control. Surveillance and prevention of hepatitis B and C in Europe. Stockholm: ECDC, 2010.
Talaat, M, et al.
Sentinel surveillance for patients with acute hepatitis in Egypt, 2001–04. Eastern Mediterranean Health Journal
2010; 16: 134–140.
Selvey, LA, et al.
Investigation of notifications of hepatitis C in 1994: the experience of three health departments. Australian and New Zealand Journal of Public Health
1996; 20: 525–529.
Robotin, MC, et al.
Surveillance for newly acquired hepatitis C in Australia [see comment]. Journal of Gastroenterology and Hepatology
2004; 19: 283–288.
Guy, R, et al.
Enhanced case detection for newly acquired hepatitis C infection: epidemiological findings and health service implications. Communicable Diseases Intelligence
2008; 32: 250–256.
Staff, MP, et al.
Public health surveillance of hepatitis C: can it identify incident cases?
Australian and New Zealand Journal of Public Health
2000; 24: 198–200.
Olmsted, RN. Is the recent increase in the reported cases of hepatitis C/NANB a real increase?
American Journal of Infection Control
1996; 24: 415–416.
Sokol, TM, et al.
Hepatitis C infection in Louisiana. Journal of the Louisiana State Medical Society
2005; 157: 98–102.
Ruf, M, et al.
Setting up an enhanced surveillance of newly acquired hepatitis C infection in men who have sex with men: a pilot in London and South East region of England. Eurosurveillance
2008; 13: pii=19042.
Finelli, L, et al.
National surveillance of dialysis-associated diseases in the United States, 2002. Seminars in Dialysis
2005; 18: 52–61.
Tokars, JI, et al.
National surveillance of dialysis associated diseases in the United States, 1995. ASAIO Journal
1998; 44: 98–107.
Tokars, JI, et al.
National surveillance of dialysis-associated diseases in the United States, 1997. Seminars in Dialysis
2000; 13: 75–85.
elSaadany, S, Gully, P, Giulivi, A. Hepatitis A, B, and C in Canada. Results from the National Sentinel Health Unit Surveillance System, 1993–1995. Canadian Journal of Public Health
2002; 93: 435–438.
Wu, H-X, et al.
Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998 to 2004. Scandinavian Journal of Infectious Diseases
2006; 38: 482–489.
Zou, S, et al.
Enhanced surveillance of acute hepatitis B and C in four health regions in Canada, 1998 to 1999. Canadian Journal of Infectious Diseases
2001; 12: 357–363.
Alter, M, et al.
Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. Journal of the American Medical Association
1990; 264: 2231–2235.
Alter, M, et al.
The natural history of community-acquired hepatitis C in the United States. New England Journal of Medicine
1992; 327: 1899–1905.
Spada, E, et al.
Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Digestive and Liver Disease
2001; 33: 778–784.
Mele, A, et al.
Integrated epidemiological system for acute viral hepatitis in Italy (SEIEVA): description and preliminary results. European Journal of Epidemiology
1986; 2: 300–304.
Mele, A, et al.
Heterosexual transmission of hepatitis C in Italy. Journal of Medical Virology
1999; 57: 111–113.
Tosti, ME, et al.
Incidence of parenterally transmitted acute viral hepatitis among healthcare workers in Italy. Infection Control and Hospital Epidemiology
2007; 28: 629–632.
Stroffolini, T, et al.
Incidence of non-A, non-B and HCV positive hepatitis in healthcare workers in Italy. Journal of Hospital Infection
1996; 33: 131–137.
Bianco, E, et al.
Case fatality rate of acute viral hepatitis in Italy: 1995–2000. An update. Digestive and Liver Disease
2003; 35: 404–408.
Centers for Disease Control and Prevention. Evaluation of acute hepatitis C infection surveillance – United States, 2008. Morbidity and Mortality Weekly Report
2010; 59: 1407–1410.
Daniels, D, et al.
Surveillance for acute viral hepatitis – United States, 2007. Morbidity and Mortality Weekly Report Surveillance Summaries
2009; 58: 1–27.
Gidding, HF, et al.
The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology and Hepatology
2009; 24: 1648–1654.
Memish, ZA, Knawy, BA, El-Saed, A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. International Journal of Infectious Diseases
2010; 14: e115–120.
Brant, LJ, et al.
Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiology and Infection
2007; 135: 417–426.
Tweed, E, et al.
Hepatitis C testing in sexual health services in England, 2002–7: results from sentinel surveillance. Sexually Transmitted Infections
2010; 86: 126–130.
Strauss, B, Bigham, M. Hepatitis C surveillance – are we doing enough? British Columbia, 2001. Canada Communicable Disease Report
2002; 28: 149–156.
Kuo, M, et al. Newly acquired hepatitis C virus infection in British Columbia, 1992–2005. Canadian Digestive Diseases Week (CDDW), the annual scientific conference of the Canadian Association of Gastroenterology (CAG). Montreal: The Canadian Association of Gastroenterology and The Canadian Association for the Study of the Liver, 2008.
Public Health Agency of Canada. Enhanced surveillance of risk behaviours among people who inject drugs. Phase I Report, August 2006. Ottawa: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2006.
Fleming, DT, et al.
Surveillance programs for chronic viral hepatitis in three health departments. Public Health Reports
2006; 121: 23–35.
Fong, F. An epidemiologic summary of the hepatitis C epidemic in Minnesota. Minnesota Medicine
2003; 86: 46–51.
Gasiorowicz, M, et al.
Epidemiologic trends in infection, mortality, and transplants related to hepatitis C in Wisconsin. Wisconsin Medical Journal
2006; 105: 34–39.
Gungabissoon, U, Balogun, MA, Ramsay, ME. Hepatitis C virus: laboratory surveillance in England and Wales, 1992–2004. Epidemiology and Infection
2007; 135: 541–548.
O'Meara, M, Barry, J, Mullen, L. Epidemiology of hepatitis C infection, ERHA/HSE Eastern region. Irish Medical Journal
2007; 100: 365–366.
Shaw, L, et al.
Establishment of a database of diagnosed HCV-infected persons in Scotland. Communicable Disease and Public Health
2003; 6: 305–310.
Chaves, S, Widdowson, MA, Bosman, A. Surveillance of HCV infection in the Netherlands [see comment]. Eurosurveillance
2003; 8: 108–113.
Duberg, A, et al.
The epidemiology of hepatitis C virus infection in Sweden. Eurosurveillance
Lim, M, et al. Hepatitis C sentinel surveillance in Victoria. In: Australasian Viral Hepatitis Conference. Brisbane, 2008.
National Centre in HIV Epidemiology and Clinical Research. Australian needle and syringe program survey national data report 2004–2008.
Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2009.
Backus, LI, et al.
Clinical case registries: simultaneous local and national disease registries for population quality management. Journal of the American Medical Informatics Association
2009; 16: 775–783.
Costa, ZB, et al.
Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil. BMC Infectious Diseases
2009; 9: 116.
Craine, N, et al.
Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection
2009; 137: 1255–1265.
Khattab, MA, et al.
Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000–2008. American Journal of Infection Control
2010; 38: 640–641.
Klevens, RM, et al.
Population-based surveillance for hepatitis C virus, United States, 2006–2007. Emerging Infectious Diseases
2009; 15: 1499–1502.
McQuillian, GM, et al.
Viral hepatitis. National Center for Health Statistics data brief
Madani, TA. Hepatitis C virus infections reported over 11 years of surveillance in Saudi Arabia. Transactions of the Royal Society of Tropical Medicine and Hygiene
2009; 103: 132–136.
Platt, L, et al.
Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. European Journal of Public Health
2009; 19: 428–433.
Sofair, AN, et al.
Use of fax-back surveillance to determine epidemiologic and clinical characteristics of patients diagnosed with hepatitis C in Waterbury, Connecticut. Connecticut Medicine
2009; 73: 593–595.
Ximenes, RAdA, et al.
Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cadernos de saúde pública
2010; 26: 1693–1704.
World Health Organization. WHO recommended surveillance standards: second edition. Geneva: World Health Organisation Department of Communicable Disease Surveillance and Response, 1999 October.
Commission of the European Communities. Commission decision of 19 March 2002 laying down case definitions for reporting communicable diseases to the community network under Decision No. 2119/98/EC of the European Parliament and of the Council. Official Journal of the European Communities
2002; L86: 44–62.
Haley, RW, Fischer, RP. The tattooing paradox – are studies of acute hepatitis adequate to identify routes of transmission of subclinical hepatitis C infection? 129th Annual Meeting of the American Public Health Association. Atlanta, Georgia: American Medical Association, 2001, 1095.
Pradat, P, et al.
Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. Hepatology
2002; 36: 973–977.
Tobin, S. Hepatitis C: enhancing routine surveillance in Victoria. Victorian Infectious Diseases Bulletin
2001; 4: 17–19.
Seeff, LB. The history of the ‘natural history’ of hepatitis C (1968–2009). Liver International
2009; 29: 89–99.
Aitken, CK, et al.
High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology
2008; 48: 1746–1752.
Grebely, J, et al.
Hepatitis C virus reinfection in injection drug users [see comment]. Hepatology
2006; 44: 1139–1145.
Mehta, SH, et al.
Protection against persistence of hepatitis C. Lancet
2002; 359: 1478–1483.
Micallef, JM, et al.
High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. Journal of Viral Hepatitis
2007; 14: 413–418.
Osburn, WO, et al.
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology
2010; 138: 315–324.
Page, K, et al.
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. Journal of Infectious Diseases
2009; 200: 1216–1226.
Pham, ST, et al.
Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology
2010; 52: 1564–1572.
van de Laar, TJW, et al.
Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam [see comment]. Journal of Hepatology
2009; 51: 667–674.
Vickerman, P, et al.
The more you look the more you find – effects of hepatitis C virus testing interval on re-infection incidence and clearance: implications for future vaccine study design. Journal of Infectious Diseases
Hope, VD, et al.
Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. Journal of Viral Hepatitis
2011; 18: 262–270.
Page-Shafer, K, et al.
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. Journal of Clinical Microbiology
2008; 46: 499–506.
Turner, KME, et al.
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction
2011; 106: 1978–1988.
European Monitoring Centre for Drugs and Drug Addiction. Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users. EMCDDA Manuals, Lisbon, 2010.
European Association for the Study of Liver Disease. International Consensus Conference on Hepatitis C Paris, 26–28 February 1999: Consensus statement. Journal of Hepatology
1999; 30: 956–961.
European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC, 2010.
Hatzakis, A, et al.
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. Journal of Viral Hepatitis
2011; 18: 1–16.
Calvaruso, V, Craxì, A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver International
2012; 32: 2–8.
Chary, A, Holodniy, M. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Reviews on Recent Clinical Trials
Gane, E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver International
2011; 31: 62–67.